Using real-world evidence to shape CAR-T care in R/R DLBCL скачать в хорошем качестве

Using real-world evidence to shape CAR-T care in R/R DLBCL

Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the importance of real-world evidence in shaping the CAR T-cell therapy care for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), highlighting its role in helping to understand the safety and efficacy of approved CAR T-cell products in a wider range of patients than those enrolled in pivotal clinical trials. Dr Iacoboni notes that efforts have been made to compare different CAR-T constructs, such as axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), in the real-world setting, using statistical methodologies like propensity score matching (PSM) and inverse probability treatment weighting (IPTW) to balance baseline variables and make populations comparable. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.